STOCK TITAN

[8-K] Cronos Group Inc. Common Share Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
falseCRONOS GROUP INC.0001656472StaynerCanada001-38403Ontario00016564722025-06-202025-06-20

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 20, 2025

CRONOS GROUP INC.
(Exact name of registrant as specified in its charter)
British Columbia, Canada
001-38403
N/A
(State or other jurisdiction(Commission(I.R.S. Employer
of incorporation)File Number)Identification No.)
4491 Concession Rd 12
Stayner, Ontario
L0M 1S0
(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (416) 504-0004

Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Shares, no par valueCRONThe NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 5.07.    Submission of Matters to a Vote of Security Holders.
Cronos Group Inc. (the “Company”) held its 2025 Annual Meeting of Shareholders on June 20, 2025 (the “Meeting”). The proposals voted upon at the Meeting and the final results of the shareholder vote on each proposal are set forth below. Each of the proposals is summarized in greater detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 25, 2025.
Proposal No. 1: Election of Directors
Name of NomineeForWithheldBroker Non-Votes
Michael Gorenstein206,219,875 17,012,443 53,757,134 
Jason Adler215,665,946 7,566,372 53,757,134 
Murray Garnick215,548,312 7,684,006 53,757,134 
Kamran Khan216,349,694 6,882,624 53,757,134 
Dominik Meier216,404,347 6,827,971 53,757,134 
Elizabeth Seegar211,177,232 12,055,086 53,757,134 
James Rudyk215,956,203 7,276,115 53,757,134 
Proposal No. 2: Adoption of an advisory (non-binding) resolution to approve the compensation of the Company’s named executive officers
ForAgainstAbstainedBroker Non-Votes
210,122,286 12,566,122 543,910 53,757,134 
Proposal No. 3: Appointment of Davidson & Company LLP, the Company’s independent registered public accounting firm, to serve as the Company’s independent auditor for fiscal year 2025 and to authorize the Board of Directors of the Company to fix the independent auditors’ remuneration
ForWithheld
273,039,223 3,950,229 





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CRONOS GROUP INC.
Dated: June 23, 2025By:/s/ Michael Gorenstein
Name: Michael Gorenstein
Title: President and Chief Executive Officer


Cronos Group

NASDAQ:CRON

CRON Rankings

CRON Latest News

CRON Stock Data

716.88M
200.43M
46.39%
14.32%
1.19%
Drug Manufacturers - Specialty & Generic
Medicinal Chemicals & Botanical Products
Link
Canada
STAYNER